Correlation Between Sarepta Therapeutics and Inhibikase Therapeutics

Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sarepta Therapeutics and Inhibikase Therapeutics, you can compare the effects of market volatilities on Sarepta Therapeutics and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Inhibikase Therapeutics.

Diversification Opportunities for Sarepta Therapeutics and Inhibikase Therapeutics

0.56

Correlation Coefficient

Sarepta Therapeutics  Inhibikase Therapeutics

Very weak diversification

The 3 months correlation between Sarepta and Inhibikase is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Inhibikase Therapeutics go up and down completely randomly.

Pair Corralation between Sarepta Therapeutics and Inhibikase Therapeutics

Given the investment horizon of 90 days Sarepta Therapeutics is expected to under-perform the Inhibikase Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Sarepta Therapeutics is 2.98 times less risky than Inhibikase Therapeutics. The stock trades about -0.22 of its potential returns per unit of risk. The Inhibikase Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  216.00  in Inhibikase Therapeutics on December 4, 2024 and sell it today you would earn a total of  11.00  from holding Inhibikase Therapeutics or generate 5.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Sarepta Therapeutics  vs.  Inhibikase Therapeutics

Sarepta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Inhibikase Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inhibikase Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward-looking signals, Inhibikase Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Sarepta Therapeutics and Inhibikase Therapeutics

The main advantage of trading using opposite Sarepta Therapeutics and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.

The idea behind Sarepta Therapeutics and Inhibikase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.